OKE vs SPRY · P/E 15, rev $21.70B vs rev $89.1M
ONEOK Inc (OKE) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
ONEOK Inc (OKE) is a oil & gas midstream company listed on NYSE.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported OKE revenue for 2024-12-31 was $21.70B. Net income was $3.11B. Revenue was up 22.7% from 2023-12-31 to 2024-12-31. OKE currently screens at market cap $53.92B and trailing P/E 15.3.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
OKE currently screens at market cap $53.92B and trailing P/E 15.3. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the OKE and SPRY stock pages for the full models.
Not investment advice.